Publications by authors named "J L Ambrus"

Sjögren's (SS) involves salivary and lacrimal gland dysfunction. These studies examined metabolic profiles in the B6. transgene mouse model of SS and a cohort of human SS patients at different stages of disease.

View Article and Find Full Text PDF

Migraine is a disabling primary headache disorder that directly affects a significant proportion of the population. Despite its widespread prevalence, migraine remains under-diagnosed and under-treated. To support clinical decision-making, we convened a panel of experts to develop a clinical approach to the diagnosis and management of migraine.

View Article and Find Full Text PDF

Purpose: To evaluate the possible role of systemic inflammation in dry eye disease (DED) via systemic inflammatory marker associations with DED signs and symptoms, and an analysis of a subgroup with Sjogren's Syndrome (SS).

Methods: Participant serums were analyzed using line immunoassays (LIAs) for the presence of antibodies against 34 systemic inflammatory markers. Using the 2012 American College of Rheumatology definition, the 481 participants were categorized into group 1 (SS;  = 52), group 2 (autoimmune disease not including SS;  = 66), or group 3 (control, i.

View Article and Find Full Text PDF

Immune cell infiltration and glandular dysfunction are the hallmarks of autoimmune diseases such as primary Sjogren's syndrome (pSS), however, the mechanism(s) is unknown. Our data show that metformin-treatment induces the salivary glands of IL14α-transgenic mice (IL14α), which is a model for pSS. Mechanistically, we show that loss of in IL14α mice.

View Article and Find Full Text PDF
Article Synopsis
  • The study identifies dansylcadaverine as a moderate inhibitor of dynamin I (dynI) GTPase activity, affecting clathrin-mediated endocytosis in U2OS cells.
  • A new class of inhibitors, termed Sulfonadyns™, showed enhanced dynI inhibition with certain chemical modifications, notably the addition of a terminal cinnamyl group.
  • The most effective compound, Sulfonadyn-47, demonstrated significant anti-seizure effects in animal tests, comparable to established medications, suggesting potential for new anti-seizure drugs targeting dynamin.
View Article and Find Full Text PDF